Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Gastrointestinal Stromal Tumor (GIST) Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Gastrointestinal Stromal Tumor (GIST) Overview | 11 | 1 |
| Pipeline Products for Gastrointestinal Stromal Tumor (GIST) Comparative Analysis | 12 | 1 |
| Gastrointestinal Stromal Tumor (GIST) Therapeutics under Development by Companies | 13 | 2 |
| Gastrointestinal Stromal Tumor (GIST) Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Gastrointestinal Stromal Tumor (GIST) Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Gastrointestinal Stromal Tumor (GIST) Products under Development by Companies | 19 | 2 |
| Gastrointestinal Stromal Tumor (GIST) Products under Investigation by Universities/Institutes | 21 | 1 |
| Gastrointestinal Stromal Tumor (GIST) Companies Involved in Therapeutics Development | 22 | 26 |
| AB Science SA | 22 | 1 |
| Advanced Accelerator Applications S.A. | 23 | 1 |
| Advenchen Laboratories, LLC | 24 | 1 |
| Ariad Pharmaceuticals, Inc. | 25 | 1 |
| Arog Pharmaceuticals, Inc. | 26 | 1 |
| ArQule, Inc. | 27 | 1 |
| Array BioPharma Inc. | 28 | 1 |
| Astex Pharmaceuticals Inc | 29 | 1 |
| Blueprint Medicines Corporation | 30 | 1 |
| Boston Biomedical, Inc. | 31 | 1 |
| Calithera Biosciences, Inc. | 32 | 1 |
| Chipscreen Biosciences Ltd | 33 | 1 |
| Daiichi Sankyo Company, Limited | 34 | 1 |
| Deciphera Pharmaceuticals, LLC | 35 | 1 |
| F. Hoffmann-La Roche Ltd. | 36 | 1 |
| Horizon Pharma Plc | 37 | 1 |
| Immunicum AB | 38 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 39 | 1 |
| Kolltan Pharmaceuticals, Inc. | 40 | 1 |
| Natco Pharma Limited | 41 | 1 |
| Nerviano Medical Sciences S.r.l. | 42 | 1 |
| Novartis AG | 43 | 1 |
| Omeros Corporation | 44 | 1 |
| Plexxikon Inc. | 45 | 1 |
| Rhizen Pharmaceuticals S.A. | 46 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 47 | 1 |
| Gastrointestinal Stromal Tumor (GIST) Therapeutics Assessment | 48 | 13 |
| Assessment by Monotherapy Products | 48 | 1 |
| Assessment by Combination Products | 49 | 1 |
| Assessment by Target | 50 | 3 |
| Assessment by Mechanism of Action | 53 | 4 |
| Assessment by Route of Administration | 57 | 2 |
| Assessment by Molecule Type | 59 | 2 |
| Drug Profiles | 61 | 135 |
| alpelisib Drug Profile | 61 | 3 |
| amcasertib Drug Profile | 64 | 2 |
| apatinib Drug Profile | 66 | 3 |
| ARQ-092 Drug Profile | 69 | 3 |
| binimetinib Drug Profile | 72 | 7 |
| BLU-285 Drug Profile | 79 | 2 |
| buparlisib hydrochloride Drug Profile | 81 | 5 |
| CB-839 Drug Profile | 86 | 7 |
| CHMFLKIT-110 Drug Profile | 93 | 1 |
| crenolanib besylate Drug Profile | 94 | 3 |
| CS-2164 Drug Profile | 97 | 1 |
| dabrafenib mesylate + trametinib dimethyl sulfoxide Drug Profile | 98 | 7 |
| DCC-2618 Drug Profile | 105 | 1 |
| everolimus Drug Profile | 106 | 11 |
| infigratinib Drug Profile | 117 | 2 |
| interferon gamma-1b Drug Profile | 119 | 4 |
| Intuvax Drug Profile | 123 | 6 |
| KTN-0158 Drug Profile | 129 | 2 |
| masitinib Drug Profile | 131 | 13 |
| nilotinib Drug Profile | 144 | 5 |
| NMSP-088 Drug Profile | 149 | 1 |
| NRCAN-019 Drug Profile | 150 | 2 |
| onalespib Drug Profile | 152 | 4 |
| Peptide to Antagonize GRPR for Oncology Drug Profile | 156 | 1 |
| pexidartinib Drug Profile | 157 | 4 |
| PLX-9486 Drug Profile | 161 | 1 |
| ponatinib hydrochloride Drug Profile | 162 | 13 |
| SF-1126 Drug Profile | 175 | 2 |
| SHR-1020 Drug Profile | 177 | 2 |
| Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors Drug Profile | 179 | 1 |
| Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor Drug Profile | 180 | 1 |
| TAS-116 Drug Profile | 181 | 1 |
| TGR-1202 Drug Profile | 182 | 7 |
| vemurafenib Drug Profile | 189 | 7 |
| Gastrointestinal Stromal Tumor (GIST) Dormant Projects | 196 | 1 |
| Gastrointestinal Stromal Tumor (GIST) Discontinued Products | 197 | 1 |
| Gastrointestinal Stromal Tumor (GIST) Product Development Milestones | 198 | 11 |
| Featured News &Press Releases | 198 | 1 |
| Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | 198 | 1 |
| Jul 13, 2016: Boston Biomedical Announces Generic Name of BBI-503: Amcasertib | 198 | 1 |
| May 24, 2016: Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting | 199 | 1 |
| Apr 20, 2016: Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research Annual Meeting | 200 | 1 |
| Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285 | 201 | 1 |
| Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets | 201 | 1 |
| Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting | 202 | 1 |
| Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors | 202 | 1 |
| Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican | 203 | 1 |
| Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig | 204 | 1 |
| Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors | 205 | 1 |
| Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors | 206 | 1 |
| Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting | 206 | 1 |
| Oct 04, 2012: AB Science Announces Acceptance Of Marketing Application For Masitinib By EMA To Treat Gleevec-resistant Gastro-intestinal Stromal Tumor | 207 | 1 |
| Feb 01, 2012: AB Science Reports Encouraging Results From Phase II Study With Its Investigational Drug, Masitinib | 207 | 2 |
| Appendix | 209 | 2 |
| Methodology | 209 | 1 |
| Coverage | 209 | 1 |
| Secondary Research | 209 | 1 |
| Primary Research | 209 | 1 |
| Expert Panel Validation | 209 | 1 |
| Contact Us | 209 | 1 |
| Disclaimer | 210 | 1 |